The SPHInX study is the first-ever randomized controlled trial (RCT) seeking to inform an area of equipoise regarding the efficacy of oral anticoagulation as adjunct therapy in systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH).
In this study, we compared the clinical efficacy and safety of various Yiqi Chinese medicine injections in chronic pulmonary heart disease (CPHD) through pairwise meta-analyses and indirect comparisons within a systematic review.
A001 Targeting ZIP12 to Modulate Intracellular Zinc and Vascular Dysfunction in Pulmonary Arterial Hypertension, A002 Role of The Protein Ttk in the Vascular Remodeling Processes in Pulmonary Artery Hyerpenstion and more.
Placental Abnormalities of Malperfusion, Inflammation, and Meconium are Associated With Persistent Pulmonary Hypertension of the Newborn, Pulmonary Hypertension-Targeted Therapies in Adult and Pediatric Patients Supported With Ventricular Assist Devices: A Systematic Review and more.
Ventilatory inefficiency, assessed by the VE/VCO2 slope during cardiopulmonary exercise testing (CPET), is a key physiological marker. However, differences in ventilatory efficiency between chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), as well as their response to treatment, remain incompletely characterized.
